Navigation Links
New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures
Date:12/9/2008

, Mechelen, Belgium; Pharmacometrics Department, UCB Pharma SA, Braine-L'Alleud, Belgium

-- Dose-Proportionality of Levetiracetam 500 mg Extended-Release Tablets from 1 g to 3 g Once Daily

Poster Session 3, Monday, December 8, 8:00 am - 1:30 (Abstract 3.263)

Ans Valgaeren, Nathalie Toublanc, Ingrid Burton, Sandrine Gelu-Mantoulet, Mona Troenaru, Christian Otoul, Maria Laura Sargentini-Maier, Armel Stockis

UCB Pharma SA, Braine-L'Alleud, Belgium; Department of Pharmacokinetics, SGS Life Science Services, Wavre, Belgium; Therapharm Recherches, Caen, France

Keppra XR cannot be substituted with any IR levetiracetam or any other antiepileptic medication at the pharmacy counter without a physician's approval.

Important Safety Information

Keppra XR(TM) extended-release tablets are indicated as adjunctive therapy in the treatment of partial onset seizures in patients 16 years of age and older with epilepsy.

Keppra XR(TM) causes somnolence, dizziness, and behavioral abnormalities. The most common adverse reactions observed with Keppra XR(TM) in combination with other AEDs were somnolence and irritability.

The adverse reactions that may be seen in patients receiving Keppra XR(TM) are expected to be similar to those seen in patients receiving immediate-release Keppra(R) tablets.

Keppra(R) immediate-release tablets cause somnolence and fatigue, coordination difficulties, and behavioral abnormalities (e.g., psychotic symptoms, suicidal ideation, and other abnormalities), as well as hematological abnormalities. In adults experiencing partial onset seizures, the most common adverse reactions observed with Keppra(R) in combination with other AEDs were somnolence, asthenia, infection and dizziness. '/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Keppra XR(TM) Extended-Release Tablets Filed with the FDA
2. UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets
3. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
4. New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting
5. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
6. SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
7. Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
8. Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting
9. Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
10. Opportunities to Highlight Type 1 Diabetes in November
11. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)..., NEW YORK, Nov. 20 Reportlinker...s available in its catalogue. ,, Global Market...http://www.reportlinker.com/p0164742/Global-Market...source=prnewswire&utm_medium=pr&utm_campai...Reproduction covers the U.S., 15 Countries in Euro...
(Date:11/20/2009)...NNEAPOLIS, Nov. 20 Biote...s for its first quarter ended September 30, 2009 w... share, on revenues of $3,263,000. This compares ...share, on revenues of $3,168,000 for the first qua...uarter results, Biotel President and CEO Steve Spr...
(Date:11/20/2009)...RANKLIN LAKES, N.J., Nov. 20 /PRNewswire-FirstCall...DX ) today announced the completion of its acquisi...ed company that develops and manufactures molecula..., In May 2009, BD and HandyLab announced an exclus...molecular assays on the HandyLab Jaguar(TM) platfo...
Breaking Medicine Technology:Reportlinker Adds Global Markets for Assisted Reproductive Devices 2009 2Biotel Announced Profitable First Quarter Ended September 30, 2009 2BD Completes Acquisition of HandyLab, Inc. 2BD Completes Acquisition of HandyLab, Inc. 3Sanofi Pasteur Begins Shipments of Fluzone 28R 29 Influenza Virus Vaccine for 2009 2010 Seasonal Influenza 52839 1Sanofi Pasteur Begins Shipments of Fluzone 28R 29 Influenza Virus Vaccine for 2009 2010 Seasonal Influenza 52839 2Sanofi Pasteur Begins Shipments of Fluzone 28R 29 Influenza Virus Vaccine for 2009 2010 Seasonal Influenza 52839 3Sanofi Pasteur Begins Shipments of Fluzone 28R 29 Influenza Virus Vaccine for 2009 2010 Seasonal Influenza 52839 4Sanofi Pasteur Begins Shipments of Fluzone 28R 29 Influenza Virus Vaccine for 2009 2010 Seasonal Influenza 52839 5Sanofi Pasteur Begins Shipments of Fluzone 28R 29 Influenza Virus Vaccine for 2009 2010 Seasonal Influenza 52839 6Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 1Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 2Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 3Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 4Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 5Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 6Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 7Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 1Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 2Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 3Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 4Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 5Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 6Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 7Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 8Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 9Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 10Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 11Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 12Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 13Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 14Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 15Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 16Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 17Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 18Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 19Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 20Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 21Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 22Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 23Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 24Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 25Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 26Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 27
...study appearing in the March,22 New England Journa...l Institutes of Healths National Institute of Arth...) have discovered a,connection between a specific ... as well as a possible host of autoimmune,diseases...ocytes (the cells,that make pigment) in the skin a...
...l utilization management,programs, ST. PAUL, Minn....manager Prime Therapeutics (Prime) today announced...ttera(R) (atomoxetine) for treating,attention defi...,study found that children who start on Strattera ... than children who started on,stimulants. Due to t...
Other Medicine Technology:Scientists Implicate Gene in Vitiligo and Other Autoimmune Diseases 2Scientists Implicate Gene in Vitiligo and Other Autoimmune Diseases 3Study Shows Children With ADHD Who Start on Strattera are More,Likely to Change Therapies 2Study Shows Children With ADHD Who Start on Strattera are More,Likely to Change Therapies 3
(Date:11/20/2009)... and Congressmen in Competitive Re-election Battle... , Washington, DC (Vocus) ...ing for re-election next year in races deemed to b...come to regret voting for House Speaker Nancy Pelo...ng Zogby International/ O’Leary Report poll...
(Date:11/20/2009)...v. 20 Samuel Gladding i...hat it means to be "happy" during the holidays. As...y in family counseling and chair of the Department... says research shows that it is the pressure to be...sion during the holidays. ,, That,s why he,s ch...
(Date:11/20/2009)...children with chronic kidney disease often fail to...visits increasing a child,s risk for serious hear...ns Children,s Center and other institutions. A rep...of American Society of Nephrology. , Researche...uring regular doctor visits to readings obtained v...
(Date:11/20/2009)...ases than with seasonal flu , , FRIDAY,...are reporting that children with asthma are more l...sonal flu. , "Asthma has been identified as a s... H1N1 influenza, present in 21 percent to 30 perce...nd fellow researchers from the Hospital for Sick C...
(Date:11/20/2009)...., Nov. 20 Omnicell, Inc...lutions to acute healthcare facilities, announced ... Piper Jaffray Healthcare Conference at the New Y...Speakers: Randall A. Lipps, founder, chairman, pr...p; CFO ,, Date: Tuesday, December 1, 2009 ,...
Breaking Medicine News(10 mins):Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 2Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 3Health News:Why Holidays Don't Have To Be 'Happy' 2Health News:High blood pressure easy to miss in children with kidney disease 2Health News:Omnicell to Present at Piper Jaffray Healthcare Conference 2
...ijing Olympics, and to provide the best for the at...ood air//, and thus remain healthy. The U.S. Depar...been exploring this option with leading institutio... Sciences. The team has joined together to a...
...s National Health Service (NHS) has angered health...better treatment// in India than in Glasgow. ... 66, are keen cyclists and had gone to Rajasthan i...ssary treatment, she was shifted to Glasgow, where...
...its of a key ingredient in Cannabis, which may hel...hown that cannabis could help fight brain, prostat...und to inhibit lung tumor growth by 50%, during st...to curb the growth and spread of cells in lung tum...
...nd cancer risk is higher among those individuals w... Epidemiological and basic science research...in D as a preventive and therapeutic cancer agent,...cations known to occur in cancer patients. ...
... begun the second reading of the controversial Men...'s third attempt in eight years to reform the 1983...ting legislation on the matter to ensure that pati...ospital will be subject to community treatment ord...
...ubside over Monday’s ghastly student massacre at...ner’ killer Cho Seung-Hui began to take form. ...nd persons, could not be any stronger than this po... unknown. He was a loner, had started a fire in a ...
Other Medicine News:Health News:British Doctor’s Pat for Indian Hospital 2Health News:Deficiency in Vitamin D Increases the Risk of Cancer 2Health News:UK Mental Health Reforms Will Do More Harm Than Good, Critics Warn 2Health News:Virginia Tech. Shooter -Human Rights or Innocent Lives 2
LB Agar
LB Broth (1X) liquid
...ng powder. pH: pH(4.7%, H 2 O): 7.0 0.2 Content...m Phosphate Dibasic: 25% Potassium Phosphate Monob...owder per liter of purified water. Autoclave. Appl...d recombinant proteins than LB media by allowing f...
Terrific Broth
Medicine Products: